Sol-Gel Technologies Operating Expenses 2016-2024 | SLGL
Sol-Gel Technologies operating expenses from 2016 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Sol-Gel Technologies Annual Operating Expenses
(Millions of US $) |
| 2023 |
$31 |
| 2022 |
$20 |
| 2021 |
$28 |
| 2020 |
$39 |
| 2019 |
$49 |
| 2018 |
$34 |
| 2017 |
$32 |
| 2016 |
$21 |
| 2015 |
$10 |
Sol-Gel Technologies Quarterly Operating Expenses
(Millions of US $) |
| 2024-06-30 |
$4 |
| 2024-03-31 |
$7 |
| 2023-12-31 |
$6 |
| 2023-09-30 |
$7 |
| 2023-06-30 |
$7 |
| 2023-03-31 |
$11 |
| 2022-12-31 |
$6 |
| 2022-09-30 |
$4 |
| 2022-06-30 |
$4 |
| 2022-03-31 |
$6 |
| 2021-12-31 |
$7 |
| 2021-09-30 |
$8 |
| 2021-06-30 |
$9 |
| 2021-03-31 |
$5 |
| 2020-12-31 |
$9 |
| 2020-09-30 |
$11 |
| 2020-06-30 |
$9 |
| 2020-03-31 |
$11 |
| 2019-12-31 |
$11 |
| 2019-09-30 |
$12 |
| 2019-06-30 |
$13 |
| 2019-03-31 |
$12 |
| 2018-12-31 |
$12 |
| 2018-09-30 |
$8 |
| 2018-06-30 |
$7 |
| 2018-03-31 |
$6 |
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2017-06-30 |
$6 |
| 2016-12-31 |
|
| 2015-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.020B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
